C7 substituted oxysterols and methods of use thereof
AssigneeSage Therapeutics, Inc.
InventorsFrancesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Andrew Griffin, Boyd L. Harrison, Daniel La
Life of this patent
Estimating the term…
Abstract
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
Claims4
A method of inducing sedation or anesthesia comprising administering to a subject an effective amount of a compound of Formula (B):
- or a pharmaceutically acceptable salt thereof, wherein:
- each of R1A and R1B is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, wherein the carbocyclyl may be saturated or partially saturated, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R1A and R1B, together with the carbon atom to which they are attached form a 3-8 membered ring;
- n is 1 or 2;
- each of R2A and R2B is independently hydrogen, halo, —ORC, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein RC is hydrogen or substituted or unsubstituted alkyl, or R2A and R2B, together with the carbon atom to which they are attached form an oxo group, wherein R2A and R2B are not both simultaneously hydrogen;
- R3 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or —ORA, wherein RA is substituted or unsubstituted alkyl;
- R4 is absent or hydrogen;
- and
- represents a single or double bond, wherein when one of is a double bond, the other is a single bond;
- when both of are single bonds, then R4 is hydrogen;
- and when one of the is a double bond, R4 is absent, or
- a pharmaceutical composition comprising said compound of Formula (B) or pharmaceutically acceptable salt thereof, and
- a pharmaceutically acceptable carrier.
A method of modulating an NMDA receptor in a subject, said method comprising administering to the subject in need thereof an effective amount of a compound of Formula (B):
- or a pharmaceutically acceptable salt thereof,
- wherein:
- each of R1A and R1B is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, wherein the carbocyclyl may be saturated or partially saturated, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or R1A and R1B, together with the carbon atom to which they are attached form a 3-8 membered ring;
- n is 1 or 2;
- each of R2A and R2B is independently hydrogen, halo, —ORC, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein RC is hydrogen or substituted or unsubstituted alkyl, or R2A and R2B, together with the carbon atom to which they are attached form an oxo group, wherein R2A and R2B are not both simultaneously hydrogen;
- R3 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or —ORA, wherein RA is substituted or unsubstituted alkyl;
- R4 is absent or hydrogen;
- and
- represents a single or double bond, wherein when one of is a double bond, the other is a single bond;
- when both of are single bonds, then R4 is hydrogen;
- and when one of the is a double bond, R4 is absent;
- or
- a pharmaceutical composition comprising said compound of Formula (B) or pharmaceutically acceptable salt thereof, and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.